 |
|
Wolfgang is the Managing Partner for the Life Science Fund. He is a dual citizen
of the U.S. and Germany and throughout his academic, industry and investor career he has
worked "across the Atlantic" and combined the best of Europe with the
capabilities unique to the U.S. His successful track record as entrepreneur,
executive and investor includes two major trade sales
(U.S. BioScience, BiPar),
and 5 IPOs (Devgen, Jerini, Micrus, OncoMethylome, Addex).
Wolfgang is the previous Chairman and current board member of Cappella (Galway,
Boston, and Bangalore), previous Chairman and current board member of
Intelligent Medical Implants (Bonn and Zug), Executive Chairman of ImmunoGenes
(Budapest and Zug), Executive Chairman of Hemacon (Düsseldorf and Bangalore),
Chairman and founder CEO of Oncoceutics (Philadelphia), Chairman at Provid (New
Brunswick), Chairman and Co-Founder at Noblegen (Boston).
As an executive and investor Wolfgang oversaw the successful developments and
market introductions of more than a dozen novel medical products, amongst them
agents such as Colony Stimulating factors and Enbrel (Hoechst in collaboration
with Immunex), Erythropoietin, Ethyol, the first radioprotective agent (U.S.
BioScience), PARP inhibitors (BiPar), and Sideguard, a bifurcational stenting device
(Cappella) etc.
Wolfgang
graduated from the Johannes Gutenberg University of Mainz, Germany, where he also obtained his doctorate degree and board certifications in
internal medicine, medical oncology, and hematology. He received extramural
training at the Medical School of the University of Colorado, Denver, the
Memorial Sloan Kettering Cancer Center, New York, and the Dana Farber Cancer
Center, Boston. He holds a Habilitation degree and venia legendi
at University of Freiburg, Germany, and had a 6 year tenure as Adjunct Professor
of Medicine at Brown University in Providence, Rhode Island, until 2005. He has
published more than 100 scientific articles. |
